Celiac disease (CD) is a serious autoimmune disorder that damages the small intestine in response to gluten. Despite affecting an estimated 1 in 100 people worldwide, current therapies rely exclusively on dietary restriction, something that is difficult to maintain and fails to prevent inadvertent exposure. To address this therapeutic gap, this project proposes a synthetically engineered Escherichia coli Nissle 1917 (EcN) probiotic pill designed to reduce gluten-induced inflammation in individuals with CD. The engineered EcN functions as an autonomous “sense-and-respond” system by detecting Nitric Oxide (NO), a key biomarker of gluten-induced intestinal inflammation, through a synthetic gene circuit. Upon NO detection via the PnorV promoter, the circuit triggers the localized secretion of interleukin-10 (IL-10), a potent anti-inflammatory cytokine, directly in the intestinal lumen. Above all, the strain is engineered with a biocontainment “kill switch” to ensure safety and precision for individuals. By modulating the mucosal immune response directly at the site of inflammation, this pill aims to suppress T-cell-mediated damage, preventing subsequent villous atrophy. This synthetic biology solution offers a proactive alternative to strict dietary management, potentially mitigating the long-term stress and damage caused by accidental gluten consumption and significantly improving the quality of life for individuals with CD.
The Gut Guardian: A “Sense-and-Respond” Probiotic for Localized Celiac Relief
School
Andover High School
Andover, MA
BioBuilderClub Season
2025-2026 Season
Category
Resources